Liquidia Corporation
LQDAHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeLiquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. Valued at $7.11B, LQDA is a mid-cap name in its sector. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Market Cap
$7.11B
Beta
0.55
P/E (TTM)
444.11
P/E (Fwd)
14.35
EPS (TTM)
$0.18
EPS (Fwd)
$5.57
ROE
28.2%
ROA
9.0%
Cash
$222.8M
Total Debt
$184.8M
Free CF
$9.6M
52W Change
449.8%
Annual Financials
Cash vs Debt
Liquidia Corporation holds $222.8M in cash against $184.8M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow comes in at $9.6M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 28.2% points to strong capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 9.0% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $15.9M (2022) to $158.3M (2025), reflecting a 894% increase over the period.
The relatively low beta of 0.55 suggests LQDA is a less volatile holding compared to the broader index. At over 50x earnings, LQDA carries valuation risk — any slowdown in growth expectations could lead to meaningful price adjustments. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing LQDA.